Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers

Autolus Therapeutics plc

Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).
Cash and marketable securities $588M at Dec 31, 2024, up from $239.6M, boosted by BioNTech deal and equity financing.
AUCATZYL commercial launch: 33 authorized treatment centers (covering ~60% of target U.S. patients); targeting 60 by end-2025.
Obe-cel under EMA/MHRA review with decisions expected H2 2025; Phase 1 SLE trial fully enrolled (6 patients), data at April R&D event.
BioNTech option for AUTO1/22 expired Feb 8, 2025, not exercised; Blackstone $30M milestone payment triggered by FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.